Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa
Bulimia Nervosa, Eating Disorders
About this trial
This is an interventional treatment trial for Bulimia Nervosa focused on measuring Binge-Eating Disorder
Eligibility Criteria
Inclusion Criteria: Meets criteria for bulimia nervosa Duration of illness is greater than 1 year Self-induces vomiting Weighs 80%-120 % of ideal weight Exclusion Criteria: Significant medical illness Current or lifetime history of schizophrenia, bipolar disorder, or other psychotic disorder, as defined by American Psychiatric Association criteria Moderate to severe depression, as defined by a score greater than 18 on the Hamilton Depression Scales Current diagnosis of organic mental disorder, factitious disorder, or malingering History of a personality disorder (e.g., schizotypal, borderline, or antisocial) that might interfere with assessment or compliance with the study procedures At risk for suicide Current psychotropic medications and current medications that affect GI function or that inhibit or induce cytochrome three A gene expression Currently pregnant, lactating, or planning to become pregnant Drug or alcohol abuse within the 3 months prior to study entry Abnormal EKG at baseline or 1 week following each upward dosage adjustment Anemia Known intolerance to erythromycin, or related antibiotics Abnormal results on liver function tests Electrolyte abnormalities
Sites / Locations
- Eating Disorders Clinic, New York State Psychiatric Institute
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Erythromycin
Placebo
Subjects with Bulimia Nervosa will take erythromycin.
Participants will take matched placebo.